Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $249.13M | $6.71M | $1.22 |
| 2025 | $240.98M | $-1.97M | $-0.36 |
| 2024 | $216.19M | $-254.25M | $-47.20 |
| 2023 | $219.08M | $930.0K | $0.17 |
| 2022 | $184.34M | $1.87M | $0.36 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $1.59 per share
Typical surprise +12.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$2.68 vs $2.63beat
- Wed, May 27$2.76 vs $2.09beat
- Tue, Feb 3$3.07 vs $1.40beat
- Thu, Nov 6$1.76 vs $1.56beat
- Tue, Aug 5$2.32 vs $2.46miss
- Wed, May 28$2.23 vs $2.75miss
Estimates and results for MLAB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MLAB's reported EPS growth of 35.7% a year over 4 years. Historical EPS growth of 36% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $4.52
- Implied price
- $81.35
- Return from $106.04
- -5.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $40.45 — -61.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| 20.0% | -19.3% | -15.6% | -12.5% | -9.7% | -7.3% |
| 25.0% | -15.9% | -12.1% | -8.8% | -6.0% | -3.4% |
| 30.0% | -12.5% | -8.6% | -5.2% | -2.2% | 0.5% |
| 35.0% | -9.2% | -5.0% | -1.5% | 1.6% | 4.3% |
| 40.0% | -5.8% | -1.5% | 2.1% | 5.3% | 8.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (2)
- Newsseekingalpha.com·4d ago·Positive
Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·4d ago·Negative
Mesa Laboratories Q1 Earnings Call Highlights Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.
View source ↗